Most-recognized gastrointestinal brands, August 2013

chris.truelove

The most-recognized brand in North America is Prilosec. The brand was most recognized by 11.5 percent of physicians in a survey conducted by Brand Institute Inc. during the first quarter of . Prilosec, comprising omeprazole, is marketed by AstraZeneca (astrazeneca.com). The drug was first approved by FDA in September 1989 for the short-term treatment of active benign gastric ulcer; for the short-term treatment of erosive esophagitis that has been diagnosed by endoscopy; for the long-term treatment of pathological hypersecretory conditions; to maintain healing of erosive esophagitis; and for acute benign gastric ulcer.

Nexium is the second most-recognized gastrointestinal brand in North America. About 10.1 percent of physicians recognize this brand the most. Nexium, comprising esomeprazole, is marketed by AstraZeneca. The product was first approved by FDA in February 2001 for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease; to maintain symptom resolution and healing of erosive esophagitis; for the short-term treatment in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis; and in combination with amoxicillin and clarithromycin for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease.

The third most-recognized gastrointestinal brand in North America is Pepcid. About 7.5 percent of physicians recognize this product the most. Pepcid, comprising famotidine, is marketed by McNeil Consumer Pharmaceuticals, a division of Johnson & Johnson (jnj.com). The product was first approved by FDA in November 1986, and is indicated for the short-term treatment of active duodenal ulcer, as maintenance therapy for duodenal ulcer patients after healing of an active ulcer, for short-term treatment of active benign gastric ulcer, for short-term treatment of gastroesophageal reflux…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS